The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000888369
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
2/07/2026
Date registered
Help: Date registered
17/07/2026
Date last updated
Help: Date last updated
17/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
17/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
MODIFY-Hip: Graded Activity Modification in Adults with Hip Pain – A Feasibility Study
Scientific title
Graded activity modification in adults with hip pain: a feasibility study (MODIFY-Hip)
Additional trial identifiers [1] 317589 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Hip pain 342348 0
Condition category
Condition code
Musculoskeletal 338481 338481 0 0
Other muscular and skeletal disorders
Physical Medicine / Rehabilitation 338482 338482 0 0
Physiotherapy

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The intervention is a physiotherapist-led graded activity modification program (MODIFY-Hip) delivered over 12 weeks. Prior to commencement of the intervention, participants complete a 2-week pre-intervention phase. During the pre-intervention phase, participants monitor their daily step count using a wearable activity monitor, complete an education session about hip pain and activity modification, and attend an initial telehealth consultation to identify meaningful aggravating activities and establish participant-specific activity goals. This information is used to tailor the subsequent 12-week intervention.

The study includes a 2-week pre-intervention phase (Weeks 0–2). The 12-week intervention then consists of three sequential 4-week phases: Phase 1 (Weeks 3–6: pain reduction), Phase 2 (Weeks 7–10: increasing physical activity and exercise loading), and Phase 3 (Weeks 11–14: gradual return to pre-injury activity).

The intervention is delivered individually by registered physiotherapists with experience in the assessment and management of hip-related pain. All consultations are delivered via telehealth (Zoom) and are tailored to the participant's symptoms, goals, aggravating activities, and physical activity levels.

Participants receive five individual physiotherapy consultations over the 12-week intervention period, occurring at approximately weeks 3, 5, 7, 9, and 12. Consultations are expected to last approximately 30–45 minutes.

Each consultation includes review of symptoms, monitoring of adherence and adverse events, review and progression of prescribed activity modification strategies, education, and collaborative planning of goals and progression for the subsequent phase of the intervention.

During Phase 1, participants work with the physiotherapist to identify meaningful aggravating activities (e.g., squatting, running) and implement activity modifications aimed at reducing hip pain. Non-aggravating activities are identified and prescribed as appropriate. During Phase 2, the physiotherapist and participant progressively increase the duration, frequency and/or intensity of previously tolerated non-aggravating physical activities according to participant goals and symptom response. During Phase 3, previously aggravating activities are reintroduced gradually by progressively increasing exposure (e.g. duration, repetitions or intensity) while monitoring symptoms. Progression occurs only when pain does not increase by more than 2 points on a 0–10 numerical pain rating scale during or following activity.

Progression between phases is guided by symptoms. Participants are required to report that pain does not increase by more than 2 points on a 0–10 numerical pain rating scale during or following activity before progressing. If symptoms worsen, adverse events occur, or the participant requests a change, the intervention may be modified or temporarily paused in consultation with the treating physiotherapist.

The intervention is delivered remotely while participants remain in their home or usual environment. Participants are asked not to commence concurrent rehabilitation or new treatments during the intervention period.

Adherence is promoted through regular physiotherapy contact, activity planning, and participant self-monitoring. Adherence is monitored using weekly participant logbooks, daily step-count monitoring, and physiotherapist consultation records documenting attendance, activity modifications, and progression through the intervention.
Intervention code [1] 334394 0
Rehabilitation
Intervention code [2] 334395 0
Lifestyle
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345768 0
Feasibility (composite outcome comprising demand and implementation) of conducting a future randomised controlled trial of a graded activity modification intervention for adults with hip-related pain.
Timepoint [1] 345768 0
Throughout the study period from participant recruitment to completion of the final assessment at 14 weeks (primary timepoint: 14 weeks after commencement of the pre-intervention phase)
Primary outcome [2] 345980 0
Intervention acceptability
Timepoint [2] 345980 0
Baseline, Week 14 (end of intervention)
Primary outcome [3] 345981 0
Practicality - Adverse Events
Timepoint [3] 345981 0
Weekly throughout the 12-week intervention period and at each physiotherapy consultation
Secondary outcome [1] 463231 0
Hip-related quality of life
Timepoint [1] 463231 0
Baseline; Week 3 (start of Phase 1); Week 14 (end of intervention)
Secondary outcome [2] 463232 0
Hip and groin symptoms and function
Timepoint [2] 463232 0
Baseline; Week 3 (start of Phase 1); Week 14 (end of intervention)
Secondary outcome [3] 463235 0
Physical activity level
Timepoint [3] 463235 0
Baseline; Week 3 (start of Phase 1); Week 14 (end of intervention)
Secondary outcome [4] 463236 0
Hip flexion strength
Timepoint [4] 463236 0
Baseline; Week 14 (end of intervention)
Secondary outcome [5] 463237 0
Hip extension strength
Timepoint [5] 463237 0
Baseline; Week 14 (end of intervention)
Secondary outcome [6] 463238 0
Hip abduction strength
Timepoint [6] 463238 0
Baseline; Week 14 (end of intervention)
Secondary outcome [7] 463239 0
Hip adduction strength
Timepoint [7] 463239 0
Baseline; Week 14 (end of intervention)
Secondary outcome [8] 463240 0
Hip internal rotation strength
Timepoint [8] 463240 0
Baseline; Week 14 (end of intervention)
Secondary outcome [9] 463241 0
Hip external rotation strength
Timepoint [9] 463241 0
Baseline; Week 14 (end of intervention)
Secondary outcome [10] 463242 0
Hip flexion range of motion
Timepoint [10] 463242 0
Baseline; Week 14 (end of intervention)
Secondary outcome [11] 463243 0
Hip extension range of motion
Timepoint [11] 463243 0
Baseline; Week 14 (end of intervention)
Secondary outcome [12] 463244 0
Hip abduction range of motion
Timepoint [12] 463244 0
Baseline; Week 14 (end of intervention)
Secondary outcome [13] 463245 0
Hip internal rotation range of motion
Timepoint [13] 463245 0
Baseline; Week 14 (end of intervention)
Secondary outcome [14] 463246 0
Hip external rotation range of motion
Timepoint [14] 463246 0
Baseline; Week 14 (end of intervention)
Secondary outcome [15] 463247 0
Lateral trunk and hip muscle endurance
Timepoint [15] 463247 0
Baseline; Week 14 (end of intervention)
Secondary outcome [16] 463248 0
Single-leg hop performance
Timepoint [16] 463248 0
Baseline; Week 14 (end of intervention)
Secondary outcome [17] 463249 0
Single-leg sit-to-stand performance
Timepoint [17] 463249 0
Baseline; Week 14 (end of intervention)
Secondary outcome [18] 463250 0
Daily step count
Timepoint [18] 463250 0
Daily throughout the 2-week pre-intervention phase and 12-week intervention period
Secondary outcome [19] 463253 0
Cognitive flexibility
Timepoint [19] 463253 0
Baseline; Week 14 (end of intervention)

Eligibility
Key inclusion criteria
I. Participants aged 18-50 year;
II. Self-reported hip (anterior, lateral or posterior) or groin pain of greater than 3/10 for at least 6 weeks;
III. A positive clinician-guided self-administered flexion, adduction, internal rotation (FADIR) test conducted via telehealth;
IV. Willing and able to modify physical activity.
Minimum age
18 Years
Maximum age
50 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
I. positive self-administered tests suggesting hip pain is referred from the spine (repeated lumbar flexion, extension and rotation in standing)
II. Self-reported inflammatory disease (e.g. rheumatoid arthritis);
III. Previous history of significant hip condition (e.g. slipped capital femoral epiphysis) or fracture;
IV. Previous hip surgery (e.g. arthroscopy or total hip replacement);
VI. Inability to understand English;
VII. Previously confirmed diagnosis of hip osteoarthritis

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
Based on Whitehead et al. (2016), using a non-centrality approach aiming for 90% power to estimate the sample size for a future definitive randomised controlled trial, a sample size of 25 participants was considered appropriate for this feasibility study.

Primary feasibility outcomes (demand, implementation, acceptability and practicality) will be analysed descriptively and compared with the predefined feasibility criteria. Recruitment, consultation attendance, weekly logbook completion, participant retention, intervention acceptability and adverse events will be summarised using descriptive statistics (frequencies, percentages, means and standard deviations, or medians and interquartile ranges where appropriate).

Secondary clinical outcomes (iHOT-33, HAGOS, IPAQ, Cognitive Flexibility Scale, hip muscle strength, hip range of motion and functional performance) will be analysed as exploratory efficacy outcomes. Continuous outcome data will be assessed for normality prior to analysis. Changes from baseline to follow-up will be analysed using linear mixed-effects models where appropriate, with time included as a fixed effect and participant ID as a random effect to account for repeated measures. Estimated mean changes with 95% confidence intervals will be reported. These outcomes will then be used to inform a sample size calculation for a fully powered randomised controlled trial.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 322144 0
Charities/Societies/Foundations
Name [1] 322144 0
Physiotherapy Research Foundation
Country [1] 322144 0
Australia
Funding source category [2] 322261 0
Government body
Name [2] 322261 0
HER knee NHMRC Centre of Excellence (CRE)
Country [2] 322261 0
Australia
Primary sponsor type
University
Name
La Trobe Sport and Exercise Medicine Research Centre
Address
Country
Australia
Secondary sponsor category [1] 325175 0
None
Name [1] 325175 0
Address [1] 325175 0
Country [1] 325175 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320675 0
La Trobe University Human Research Ethics Committee
Ethics committee address [1] 320675 0
Ethics committee country [1] 320675 0
Australia
Date submitted for ethics approval [1] 320675 0
13/11/2025
Approval date [1] 320675 0
16/01/2026
Ethics approval number [1] 320675 0
HEC25500

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151246 0
Dr Michael JM O'Brien
Address 151246 0
La Trobe University, Bundoora, VIC 3086
Country 151246 0
Australia
Phone 151246 0
+61 0394792418
Fax 151246 0
Email 151246 0
m.o'[email protected]
Contact person for public queries
Name 151247 0
Michael JM O'Brien
Address 151247 0
La Trobe University, Bundoora, VIC 3086
Country 151247 0
Australia
Phone 151247 0
+61 0394792418
Fax 151247 0
Email 151247 0
m.o'[email protected]
Contact person for scientific queries
Name 151248 0
Michael JM O'Brien
Address 151248 0
La Trobe University, Bundoora, VIC 3086
Country 151248 0
Australia
Phone 151248 0
+61 0394792418
Fax 151248 0
Email 151248 0
m.o'[email protected]

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: m.o'[email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.